BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.71
$0.879.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | -30.30% | -42.82% | |||
| Total Depreciation and Amortization | 248.08% | 3.85% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -62.35% | -39.72% | |||
| Change in Net Operating Assets | -63.69% | -70.60% | |||
| Cash from Operations | -185.63% | -121.08% | |||
| Capital Expenditure | -1,550.00% | -1,057.14% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | 106.52% | 545.47% | |||
| Cash from Investing | 106.36% | 542.47% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -88.85% | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | -90.50% | -106.08% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -86.72% | -2,763.79% | |||